New Insights into the French Paradox: Free Radical Scavenging by Resveratrol Yields Cardiovascular Protective Metabolites
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Orinamhe G Agbadua und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacognosy, University of Szeged, Eötvös str. 6, H-6720 Szeged, Hungary. Hauptthemen laut MEDLINE: Benzofurans, Free Radical Scavengers, Stilbenes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nemzeti Kutat?si, Fejleszt?si ?s Innovaci?s Alap, Innov?ci?s ?s Technol?giai Miniszt?rium.
Abstract (Originalsprache)
Resveratrol was subjected to a diversity-oriented synthesis using oxidative transformations by various biorelevant, biomimetic, or biomimetic-related chemical reagents. Using a combined strategy of ultrahigh-resolution profiling, bioactivity screening, and bioactivity-guided isolation, 19 metabolites were obtained. The compounds were tested for their in vitro enzyme inhibitory activity on angiotensin-1 converting enzyme (ACE), cyclooxygenase-1 and -2, and 15-lipoxygenase (LOX), and evaluated for their relevant drug-like properties in silico. The compounds demonstrated a generally increased cardiovascular protective and anti-inflammatory potential and better drug-likeness compared to resveratrol. Trans-δ-viniferin (6) was identified as a competitive, C-domain-selective ACE inhibitor that is over 20 times more potent than resveratrol. Further, trans-ε-viniferin (2) acted as an over 40 times stronger LOX inhibitor than resveratrol. While our results cannot be directly translated to the health benefits of dietary resveratrol consumption without further studies, it is demonstrated that biologically relevant oxidative environments transform resveratrol into potent cardiovascular protective and anti-inflammatory metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacognosy, University of Szeged, Eötvös str. 6, H-6720 Szeged, Hungary.
- Institute of Pharmaceutical Analysis, University of Szeged, Somogyi str. 4, H-6720 Szeged, Hungary.
- Department of Organic Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/a, H-1117 Budapest, Hungary.
- NMR Group, Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, H-1111 Budapest, Hungary.
- Department of Pharmaceutical Chemistry, Semmelweis University, H-1092 Budapest, Hungary.
- Center for Pharmacology and Drug Research & Development, Semmelweis University, H-1085 Budapest, Hungary.
ORCID-Profile: Róbert Berkecz, György T Balogh, Laurence Marcourt, Jean-Luc Wolfender, Attila Hunyadi
Förderung
- Nemzeti Kutat?si, Fejleszt?si ?s Innovaci?s Alap
- Innov?ci?s ?s Technol?giai Miniszt?rium
Zitieren
APA
Agbadua, O. G., Kúsz, N., Berkecz, R., Vass, E., Csámpai, A., Tóth, G., Balogh, G. T., Marcourt, L., Wolfender, J. L., Queiroz, E. F., & Hunyadi, A. (2025). New Insights into the French Paradox: Free Radical Scavenging by Resveratrol Yields Cardiovascular Protective Metabolites. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03061
Vancouver
Agbadua OG, Kúsz N, Berkecz R, Vass E, Csámpai A, Tóth G, et al. New Insights into the French Paradox: Free Radical Scavenging by Resveratrol Yields Cardiovascular Protective Metabolites. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03061
BibTeX
@article{Agbadua2025,
author = {Agbadua, Orinamhe G and Kúsz, Norbert and Berkecz, Róbert and Vass, Elemér and Csámpai, Antal and Tóth, Gábor and Balogh, György T and Marcourt, Laurence and Wolfender, Jean-Luc and Queiroz, Emerson Ferreira and Hunyadi, Attila},
title = {New Insights into the French Paradox: Free Radical Scavenging by Resveratrol Yields Cardiovascular Protective Metabolites},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03061}
}
EUVIMED